-
Je něco špatně v tomto záznamu ?
Combined use of galectin-3 and thyroid peroxidase improves the differential diagnosis of thyroid tumors
D. Kalfert, M. Ludvikova, I. Kholova, J. Ludvik, O. Topolocan, J. Plzak,
Jazyk angličtina Země Slovensko
Typ dokumentu časopisecké články
- MeSH
- autoantigeny genetika MeSH
- diferenciální diagnóza MeSH
- galektin 3 genetika MeSH
- jodidperoxidasa genetika MeSH
- lidé MeSH
- nádorové biomarkery genetika MeSH
- nádory štítné žlázy klasifikace diagnóza MeSH
- proteiny vázající železo genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The differential diagnosis of well-differentiated tumors of follicular cell origin remains the most problematic task in thyroid pathology. Specific morphologic criteria (capsular and/or vascular invasion, nuclear characteristics) are crucial in the diagnosis of these neoplasms. However, the assessment of malignant features is inconclusive in some cases. Moreover, oncocytic thyroid tumors remain controversial in a respect to their pathobiology, behavior and management. Therefore, the useful diagnostic/prognostic thyroid markers are awaited. The aim of our study was to evaluate the expression of galectin-3 and thyroid peroxidase (TPO) in benign and malignant thyroid tumors of follicular cell origin. A total of 186 archival thyroid samples including 38 non-oncocytic follicular adenomas, 53 oncocytic (Hürthle cell) adenomas, 6 non-oncocytic follicular carcinomas, 23 oncocytic (Hürthle cell) carcinomas, 43 non-oncocytic papillary carcinomas, and 23 oncocytic papillary carcinomas were analyzed for galectin-3 and TPO expression by immunohistochemistry. Both types of papillary carcinomas showed significant upregulation of galectin-3 in comparison with the other tumor types, likewise, significant differences in galectin-3 expression were discovered between non-oncocytic and oncocytic variants of studied tumors excluding follicular carcinoma. Significant lowering of TPO was revealed in oncocytic adenomas and papillary carcinomas. In conclusion, the combined use of galectin-3 and TPO markers could help to improve the differential diagnosis of thyroid tumors. Differences in the galectin-3 and TPO expression between some oncocytic and non-oncocytic tumors support their separation in the latest WHO classification of thyroid tumors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005658
- 003
- CZ-PrNML
- 005
- 20200519140851.0
- 007
- ta
- 008
- 200511s2020 xo f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4149/neo_2019_190128N86 $2 doi
- 035 __
- $a (PubMed)31777257
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Kalfert, D $u Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Motol, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Combined use of galectin-3 and thyroid peroxidase improves the differential diagnosis of thyroid tumors / $c D. Kalfert, M. Ludvikova, I. Kholova, J. Ludvik, O. Topolocan, J. Plzak,
- 520 9_
- $a The differential diagnosis of well-differentiated tumors of follicular cell origin remains the most problematic task in thyroid pathology. Specific morphologic criteria (capsular and/or vascular invasion, nuclear characteristics) are crucial in the diagnosis of these neoplasms. However, the assessment of malignant features is inconclusive in some cases. Moreover, oncocytic thyroid tumors remain controversial in a respect to their pathobiology, behavior and management. Therefore, the useful diagnostic/prognostic thyroid markers are awaited. The aim of our study was to evaluate the expression of galectin-3 and thyroid peroxidase (TPO) in benign and malignant thyroid tumors of follicular cell origin. A total of 186 archival thyroid samples including 38 non-oncocytic follicular adenomas, 53 oncocytic (Hürthle cell) adenomas, 6 non-oncocytic follicular carcinomas, 23 oncocytic (Hürthle cell) carcinomas, 43 non-oncocytic papillary carcinomas, and 23 oncocytic papillary carcinomas were analyzed for galectin-3 and TPO expression by immunohistochemistry. Both types of papillary carcinomas showed significant upregulation of galectin-3 in comparison with the other tumor types, likewise, significant differences in galectin-3 expression were discovered between non-oncocytic and oncocytic variants of studied tumors excluding follicular carcinoma. Significant lowering of TPO was revealed in oncocytic adenomas and papillary carcinomas. In conclusion, the combined use of galectin-3 and TPO markers could help to improve the differential diagnosis of thyroid tumors. Differences in the galectin-3 and TPO expression between some oncocytic and non-oncocytic tumors support their separation in the latest WHO classification of thyroid tumors.
- 650 _2
- $a autoantigeny $x genetika $7 D001324
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a diferenciální diagnóza $7 D003937
- 650 _2
- $a galektin 3 $x genetika $7 D037502
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jodidperoxidasa $x genetika $7 D007453
- 650 _2
- $a proteiny vázající železo $x genetika $7 D033862
- 650 _2
- $a nádory štítné žlázy $x klasifikace $x diagnóza $7 D013964
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ludvikova, M $u Institute of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Kholova, I $u Department of Pathology, Fimlab Laboratories and Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.
- 700 1_
- $a Ludvik, J $u Department of Imaging Methods, University Hospital Pilsen, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
- 700 1_
- $a Topolocan, O $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Plzak, J $u Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Motol, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 67, č. 1 (2020), s. 164-170
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31777257 $y Pubmed
- 910 __
- $a ABA008 $b A 1194 $c 659 $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200519140847 $b ABA008
- 999 __
- $a ok $b bmc $g 1524516 $s 1095714
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 67 $c 1 $d 164-170 $e 20191118 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
- LZP __
- $a Pubmed-20200511
